Press Releases

According to IMARC Group’s report titled “India Biopsy Devices Market Size, Share, Trends and Forecast by Procedure Type, Product, Application, Guidance Technique, End User, and Region, 2026-2034“, the report offers a comprehensive analysis of the industry, including market share, forecast, growth and regional insights.

Market Outlook

The biopsy devices industry in India reached a value of USD 93.67 Million in 2025 to USD 99.00 Million in 2026 and is projected to reach USD 161.76 Million by 2034, growing at a compound annual growth rate of 5.73% during 2026-2034.

The overall market demonstrates sustained structural growth driven by escalating cancer prevalence, a rapidly expanding healthcare infrastructure, and a definitive clinical shift toward minimally invasive diagnostic procedures. Capital deployment is fundamentally accelerated by the integration of AI-enabled multi-modal imaging, automation in tissue sampling, and increased government support for oncology programs, positioning the sector as a critical anchor within India's advanced diagnostic ecosystem.

High-Intent Baseline Data

• Market Value (2025): USD 93.67 Million
• Market Value (2026): USD 99.00 Million
• Forecast Market Value (2034): USD 161.76 Million
• CAGR (2026-2034): 5.73%
• Base Year: 2025
• Forecast Years: 2026-2034

What are the Key Developments and Emerging Shifts in the India Biopsy Devices Market?

• Minimally Invasive Diagnostics Transition: The domestic healthcare sector is aggressively transitioning away from conventional, high-risk surgical biopsies. By structurally integrating highly sensitive, needle-based biopsy guns, medical practitioners systematically eliminate procedural trauma and extended recovery periods. This clinical shift fundamentally ensures continuous, high-volume procurement of single-use, automated core needles across the overall market.
• Smart Device and Automation Integration: Driven by the urgent need for rapid, error-free tissue sampling in high-density diagnostic centers, the industry is aggressively adopting smart biopsy systems. The deployment of automated, spring-loaded biopsy architectures significantly reduces operator complexity and procedural times, structurally revolutionizing the baseline standard of care for oncology diagnostics continuously.
• Real-Time Visual Guidance Standardization: Tertiary care centers are rigorously mandating the integration of advanced imaging modalities alongside biopsy extraction. By legally and clinically coupling ultrasound and magnetic resonance imaging (MRI) with biopsy procedures, radiologists secure absolute precision in tumor targeting. This critical technological convergence heavily drives continuous procurement of specialized, MRI-compatible biopsy needles nationwide.
• Geriatric Oncology Infrastructure Expansion: With demographic projections indicating India's senior citizen population will reach approximately 230 million by 2036, corporate healthcare consortiums are structurally upgrading geriatric oncology wards. This massive demographic shift actively forces the mass integration of highly precise, low-impact diagnostic tools to safely manage the exponential rise in age-related cancers.
• Diagnostic Network Democratization: The aggressive expansion of organized diagnostic chains into Tier-2 and Tier-3 urban clusters structurally disrupts legacy healthcare bottlenecks. By establishing well-equipped, localized oncology centers, corporate entities drastically reduce geographic barriers to early cancer detection, generating sustained bulk procurement of biopsy forceps and localization wires continuously.

What Factors are Driving Growth in the India Biopsy Devices Market?

• The aggressive escalation in chronic oncological ailments—specifically breast, lung, colorectal, and prostate cancers—acts as a massive primary structural growth catalyst. Changing lifestyle dynamics and rising environmental stressors actively force the mass integration of early-stage screening protocols. This directly drives unprecedented corporate procurement of specialized tissue extraction equipment across the overall market continually.
• Intensive corporate capital deployment into the domestic tertiary healthcare sector actively catalyzes localized oncology expansion. With robust structural demand for high-end diagnostic infrastructure, major hospital chains are aggressively integrating state-of-the-art pathology labs. This structural support successfully ensures that highly resilient, minimally invasive biopsy tools seamlessly reach expanding domestic clinical nodes continually.
• Strict post-pandemic health awareness actively incentivizes massive retail shifts toward preventive medical checkups. Heightened consumer consciousness regarding early disease detection actively encourages vast urban demographics to participate in organized cancer screening programs, driving aggressive, high-volume market expansion for diagnostic consumables continuously.
• Massive decentralized government initiatives promoting cancer awareness heavily stimulate organized regional health responses. By actively funding nationwide diagnostic camps, the public health sector systematically creates a highly structured baseline demand for cost-effective, precision-engineered biopsy needles across vast demographic groups.
• The widespread technological execution of advanced breast cancer screening programs heavily dictates corporate product pipelines. As specialized women's health clinics prioritize rapid and accurate tumor differentiation, the healthcare sector systematically creates a highly structured demand pipeline for vacuum-assisted biopsy systems, heavily boosting specialized commercial deployment continuously.

➤ Request Sample Report (TOC & Charts): https://www.imarcgroup.com/india-biopsy-devices-market/requestsample

How Is the Market Segmented?

Procedure Type Insights:

• Surgical Biopsy
• Needle Biopsy

Needle biopsy exhibits a clear dominance with a 62.3% share of the total market in 2025.

Product Insights:

• Biopsy Guidance Systems
• Needle Based Biopsy Guns
• Biopsy Needles
• Biopsy Forceps
• Others

Biopsy needles dominate with a market share of 32.4% of the total market in 2025.

Application Insights:

• Breast Biopsy
• Lung Biopsy
• Colorectal Biopsy
• Prostate Biopsy
• Others

Guidance Technique Insights:

• Ultrasound-guided Biopsy
• Stereotactic-guided Biopsy
• MRI-guided Biopsy
• Others

End User Insights:

• Hospitals and Clinics
• Academic and Research Institutes
• Others

Regional Insights:

• North India
• West and Central India
• South India
• East India

West and Central India lead with a market share of 31.5% of the total market in 2025.

Recent Market Developments

• The Department for Promotion of Industry and Internal Trade aggressively expanded PLI financial allocations for the medical devices category, rapidly securing massive localized capital subsidies to heavily boost high-yield domestic biopsy gun manufacturing.
• The CDSCO strictly implemented modernized Medical Device Rules, legally mandating superior biocompatibility and precision testing protocols to systematically accelerate the mass deployment of safe, globally standardized biopsy needles completely.
• Major domestic med-tech consortiums structurally executed massive technological shifts toward AI-integrated, ultrasound-guided biopsy systems, fundamentally upgrading diagnostic precision and early detection capabilities for expanding oncology demographics continuously.

Competitive Landscape

The India biopsy devices market features a semi-consolidated competitive landscape characterized by the presence of prominent global medical device manufacturers and an agile network of domestic distributors. Competition is heavily centered on technological differentiation, with major players investing in AI-integrated imaging, single-use disposable devices, and automation. Global entities leverage expansive product portfolios to secure institutional hospital contracts, while domestic operators focus on cost efficiency and last-mile distribution across tier-2 markets. Key innovators actively shaping the clinical ecosystem include global and regional players such as Terumo India, Mammotome, and Univlabs Technologies.

➤ Shape the Data to Answer Your Specific Questions - Request Customization: https://www.imarcgroup.com/request?type=report&id=3211&flag=E

Frequently Asked Questions (FAQs)

1. How big is the India biopsy devices market?

According to IMARC Group, the India biopsy devices market size reached USD 93.7 Million in 2025.

2. What is the expected market expansion by 2034?

IMARC Group expects the overall market to reach USD 161.76 Million by 2034, exhibiting a CAGR of 5.73% during 2026-2034.

3. Which procedure type dominates the market?

According to IMARC Group, needle biopsy exhibits a clear dominance, securing a 62.3% market share in 2025 due to its minimally invasive nature and widespread clinical acceptance.

4. Which product segment leads the demand?

IMARC Group states that biopsy needles represent the primary product segment driving robust diagnostic procurement, driven by their versatility and critical role in precise tissue sampling.

5. Which end-user segment holds the largest market share?

According to IMARC Group, hospitals and clinics lead the market with a share of 55.2% in 2025, supported by their advanced diagnostic infrastructure and high patient footfall for cancer-related procedures.

Strategic Insight & Verdict:

The India biopsy devices market is executing a massive structural expansion fundamentally engineered by the CDSCO’s regulatory mandates and the DPIIT’s PLI frameworks. As the government rigorously enforces the Ayushman Bharat PM-JAY scheme for oncological care and subsidizes advanced med-tech infrastructure, historical reliance on crude, substandard diagnostic devices is permanently vanishing. For corporate stakeholders, state-backed healthcare formalization successfully secures a highly lucrative, permanently optimized environment for premium, minimally invasive diagnostic investments.